Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study

Journal of Alzheimer's Disease

Volumn 38, Issue 3, 2014, Pages 515-531

  Kiddle, Steven J ^a,b   Sattlecker, Martina ^a,b   Proitsi, Petroula ^a   Simmons, Andrew ^a,b   Westman, Eric ^c   Bazenet, Chantal ^a   Nelson, Sally K ^d   Williams, Stephen ^d   Hodges, Angela ^a   Johnston, Caroline ^a,b   Soininen, Hilkka ^e   Kłoszewska, Iwona ^f   Mecocci, Patrizia ^g   Tsolaki, Magda ^h   Vellas, Bruno ⁱ   Newhouse, Stephen ^a,b   Lovestone, Simon ^a,b   Dobson, Richard J B ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b King s College London   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SomaLogic Inc   (United States)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g UNIVERSITY OF PERUGIA   (Italy)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Alzheimer's disease; biomarkers; blood; magnetic resonance imaging; nucleotide aptamers; proteome

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN E; APTAMER; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3;

ALZHEIMER DISEASE; BRAIN REGION; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REPLICATION STUDY; REVIEW; SYSTEMATIC REVIEW;

ALZHEIMER'S DISEASE; BIOMARKERS; BLOOD; MAGNETIC RESONANCE IMAGING; NUCLEOTIDE APTAMERS; PROTEOME;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; DISEASE PROGRESSION; HUMANS; PROTEOME;

EID: 84889664846     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130380     Document Type: Review

References (66)

1. Frankfort SV, Turner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH (2008) Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: A review of recent literature. Curr Clin Pharamacol 3, 123-131.
2. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
3. Bazenet C, Lovestone S (2012) Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Biomarkers Med 6, 441-454.
4. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS (2012) Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm 119, 843-850.
5. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050.
6. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL,Ward MA, Lovestone S (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21, 585-596.
7. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
8. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R, Texas Alzheimer's Research Consortium (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077.
9. Lista S, Faltraco F, Prvulovic D, Hampel H (2013) Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 101-102, 1-17.
10. Zürbig P, Jahn H (2012) Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis 33, 3617-3630.
11. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29.
12. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27, 29-34.
13. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists usingDAVID bioinformatics resources. Nat Protoc 4, 44-57.
14. Huang DW, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13.
15. Maere S, Heymans K, Kuiper M (2005) BiNGO: A Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks. Bioinformatics 21, 3448-3449.
16. Muthusamy B, Hanumanthu G, Suresh S, Rekha B, Srinivas D, Karthick L, Vrushabendra BM, Sharma S, Mishra G, Chatterjee P, Mangala KS, Shivashankar HN, Chandrika KN, Deshpande N, Suresh M, Kannabiran N, Niranjan V, Nalli A, Prasad TS, Arun KS, Reddy R, Chandran S, Jadhav T, Julie D, Mahesh M, John SL, Palvankar K, Sudhir D, Bala P, Rashmi NS, Vishnupriya G, Dhar K, Reshma S, Chaerkady R, Gandhi TK, Harsha HC, Mohan SS, Deshpande KS, Sarker M, Pandey A (2005) Plasma Proteome Database as a resource for proteomics research. Proteomics 5, 3531-3536.
17. Shannon P, Markiel A, Ozier O, Baliga NS,Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504.
18. Lovestone S, Francis P, Strandgaard K (2007) Biomarkers for disease modification trials-The innovative medicines initiative and AddNeuroMed. J Nutr Health Aging 11, 359-361.
19. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund LO, Ward M, AddNeuroMed, Consortium (2009) AddNeuroMed - The European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180, 36-46.
20. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255, 1712-1720.
21. Thambisetty M, Simmons A,Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
22. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, ForemanT, Fowler C,Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, e15004.
23. Westman E, Aguilar C, Muehlboeck JS, Simmons A (2013) Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr 26, 9-23.
24. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C, AddNeuroMed consortium (2009) MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 1180, 47-55.
25. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C (2011) The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: Experience from the first 24 months. Int J Geriatr Psychiatry 26, 75-82.
26. Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Weiner MW, Lovestone S, Spenger C, Wahlund LO, AddNeuroMed consortium, Alzheimer's Disease Neuroimaging Initiative (2011) AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 58, 818-828.
27. Westman E, Simmons A, Zhang Y, Muehlboeck JS, Tunnard C, Liu Y, Collins L, Evans A, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Lovestone S, Spenger C, Wahlund LO, AddNeuroMed consortium (2011) Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 54, 1178-1187.
28. Sing T, Sander O, Berenwinkel N, Lengauer T (2005) ROCR: Visualizing classifier performance in R. Bioinformatics 21, 3940-3941.
29. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293, 1566-1570.
30. Yu HL, Chertkow HM, Bergman H, Schipper HM (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3, 2240-2248.
31. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, Kupchak P, Kireeva I, Ingratta L, Jackowski G (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244-256.
32. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, Leu SJ (2006) Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 21, 155-161.
33. Liao PC, Yu L, Kuo CC, Kuo YM (2007) Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin Appl 1, 506-512.
34. Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P (2008) The discovery and early validation of novel plasma biomarkers in mild-To-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13, 618-636.
35. Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Wilĺe DR, Wu W, Yates JW, Gloger IS (2008) Proteomic identification and early validation of complement 1 inhibitor and pigment epitheliumderived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Prot Clin Appl 2, 467-477.
36. Mhyre TR, Loy R, Tariot PN, Profenno LA, Maguire-Zeiss KA, Zhang D, Coleman PD, Federoff HJ (2008) Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging 29, 1631-1643.
37. Ijsselstijn L, Dekker LJ, Stingl C, van der Weiden MM, Hofman A, Kros JM, Koudstaal PJ, Sillevis Smitt PA, Ikram MA, Breteler MM, Luider TM (2011) Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. J Proteome Res 10, 4902-4910.
38. Henkel AW, Müller K, Lewczuk P, Müller T, Marcus K, Kornhuber J, Wiltfang J (2012) Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: A pilot study. J Neural Transm 119, 779-788.
39. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swen son F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer. Arch Neurol 69, 1310-1317.
40. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarker and Lifestyle Research Group (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
41. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging, Initiative (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
42. Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A,Westman E, Pike I,Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R, Alzheimers Disease Neuroimaging Initiative (2012) Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One 7, e44260.
43. Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, Sojkova J, Kinsey A, Lynham S, Zhou Y, Ferrucci L, Wong DF, Lovestone S, Resnick SM (2010) Proteome-based plasma markers of brain amyloid- deposition in non-demented older individuals. J Alzheimers Dis 22, 1099-1109.
44. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmström J, Ossola R, Watts JD, Lin B, Zhang H, Moritz RL, Aebersold R (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10, M110.006353.
45. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1, 55-66.
46. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D, AIBL Research Group (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687.
47. Resnick SM, GoldszalAF,Davatzikos C, Golski S, KrautMA, Metter EJ, Bryan RN, Zonderman AB (2000) One-year age changes in MRI brain volumes in older adults. Cereb Cortex 10, 464-472.
48. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65, 45-53.
49. Waring S, O'Bryant SE, Reisch JS, Diaz-Arrastia R, Knebl J, Doody R, Texas Alzheimer's Research Consortium (2008) The Texas Alzheimer's Research Consortium longitudinal research cohort: Study design and baseline characteristics. Texas Public Health J 60, 10-13.
50. Robinson W, Nikrad MP, Robinson S, Williams S, Ostroff R (2010) New SOMAmer-based assay to discover biomarkers relevant to malignant melanoma. AACR Meeting Abstracts, A10.
51. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN (2010) Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5, e15003.
52. Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7, e46091.
53. Baird GS, Nelson SK, Keeney TR, Stewart A, Williams S, Kraemer S, Peskind ER, Montine TJ (2012) Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol 180, 446-456.
54. Lourdusamy A, Newhouse S, Lunnon K, Proitsi P, Powell J, Hodges A, Nelson SK, Stewart A, Williams S, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Lovestone S; AddNeuroMed Consortium, Dobson R, Alzheimer's Disease Neuroimaging Initiative (2012) Identification of cisregulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet 21, 3719-3726.
55. Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B (1988) Acute-phase proteins in Alzheimer's disease. Eur Neurol 28, 30-33.
56. Maes OC, Kravitz S, Mawal Y, Su H, Liberman A, Mehindate K, Berlin D, Sahlas DJ, Chertkow HM, Bergman H, Melmed C, Schipper HM (2006) Characterization of -1-Antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis 24, 89-100.
57. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S, AddNeuroMed Consortium (2011) Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 6, e28527.
58. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M (2009) Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. J Alzheimers Dis 17, 115-123.
59. Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305, 1322-1326.
60. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimer's Research&Care Consor tium, Alzheimer's Disease Neuroimaging Initiative (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
61. Wolf H, Grunwald M, Kruggel F, Riedel-Heller SG, Angerhöfer S, Hojjatoleslami A, Hensel A, Arendt T, Gertz H (2001) Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly. Neurobiol Aging 22, 177-186.
62. Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC (2005) Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord 19, 338-344.
63. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10, 1-24.
64. AiyazM,LuptonMK,Proitsi P, Powell JF,Lovestone S (2012) Complement activation as a biomarker for Alzheimer's disease. Immunobiology 217, 204-215.
65. Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL (2005) Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 19, 55-66.
66. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S (2012) Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2, e82.